Clinical Trial Update: A Study in Patients With Fabry Disease Who Are on Chronic Hemodialysis Therapy for Treatment of End-stage Renal Insufficiency. [Phase 4]

View source ↗

Summary

A Phase 4 study evaluating treatment for Fabry disease in patients on chronic hemodialysis has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fabry Disease

Drugs mentioned

• FABRAZYME (Agalsidase beta)

Snippet

Sponsor: Genzyme, a Sanofi Company | Conditions: Fabry Disease | Phase 4 | Status: WITHDRAWN